---
type: "Topics"
locale: "en"
url: "https://longbridge.com/en/topics/30699337.md"
description: "$INNOVENT BIO(01801.HK)1. Innovent Biologics' bispecific antibody data shines, with stock price surging over 119% this year.Innovent Biologics (01801.HK) disclosed clinical data for the PD-1/IL-2 bispecific antibody IBI363 at the 2025 ASCO annual meeting, showing outstanding performance in safety, efficacy, and long-term survival benefits, driving the stock price to a maximum increase of 119% this year, with market capitalization exceeding HKD 130 billion.As a leader in China's biopharmaceutical innovation, Innovent Biologics secured 8 oral presentations at the ASCO conference in the first half of the year, accounting for 2% of the global total, setting a record for domestic pharmaceutical companies.After three years of a capital winter for innovative drugs, Innovent Biologics has reached a turning point in profitability: 2024 revenue reached RMB 9.422 billion, with losses narrowing by 90% to RMB 94.63 million; Q1 2025 revenue was RMB 2.4 billion, maintaining a 41% year-on-year growth rate.The core product Sintilimab (Tyvyt) has expanded to 8 indications, with 2024 sales reaching RMB 3.8 billion; the bevacizumab biosimilar Byvasda achieved hospital sales of RMB 1.622 billion in 2023, maintaining growth despite centralized procurement pressures.In the non-oncology field, the PCSK9 inhibitor IBI306 was included in the national reimbursement drug list in 2024, with sales potential being favored by institutions. Institutions predict that non-oncology product revenue will surge from RMB 540 million in 2024 to RMB 3.27 billion in 2026."
datetime: "2025-06-13T11:51:52.000Z"
locales:
  - [en](https://longbridge.com/en/topics/30699337.md)
  - [zh-CN](https://longbridge.com/zh-CN/topics/30699337.md)
  - [zh-HK](https://longbridge.com/zh-HK/topics/30699337.md)
author: "[龙虾导导2026](https://longbridge.com/en/profiles/17698571.md)"
---

# $INNOVENT BIO(01801.HK)1. Innovent Biologics' bisp…


### Related Stocks

- [01801.HK](https://longbridge.com/en/quote/01801.HK.md)